1. Comparison of Secukinumab and Ixekizumab in psoriasis: a real‐life cohort study on the efficacy and drug survival of 445 patients. (7th November 2021) Authors: Cariti, C.; Dapavo, P.; Mastorino, L.; Ortoncelli, M.; Siliquini, N.; Merli, M.; Avallone, G.; Giordano, S.; Fabrizio, R.; Susca, S.; Verrone, A.; Stroppiana, E.; Quaglino, P.; Ribero, S. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 3(2022) Page Start: e233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis. (31st December 2023) Authors: Mastorino, L.; Gelato, F.; Quaglino, P.; Ortoncelli, M.; Ribero, S. Journal: Journal of dermatological treatment Issue: Volume 34:Number 1(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Impact of comorbidities in the response of atopic patients treated with dupilumab: a real‐life study up to 36 weeks. (26th July 2022) Authors: Mastorino, L.; Cantafio Duò, V.L.; Vecco, C.; Gelato, F.; Giordano, S.; Roccuzzo, G.; Cavaliere, G.; Avallone, G.; Ortoncelli, M.; Ribero, S.; Quaglino, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 12(2022) Page Start: e1021 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Real‐life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. (24th March 2022) Authors: Avallone, G.; Cariti, C.; Dapavo, P.; Ortoncelli, M.; Conforto, L.; Mastorino, L.; Roccuzzo, G.; Cavallo, F.; Rubatto, M.; Quaglino, P.; Ribero, S. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 7(2022) Page Start: e574 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Risankizumab shows faster response in bio naïve than in bio‐experienced psoriatic patients. (22nd June 2022) Authors: Mastorino, L.; Castelli, F.; Stroppiana, E.; Verrone, A.; Ortoncelli, M.; Susca, S.; Boskovic, S.; Passerini, S.G.; Macagno, N.; Cariti, C.; Licciardello, M.; Solaroli, C.; Pertusi, G.; Aragone, M.G.; Baggini, G.; Addese, C.; Leporati, C.; Peila, R.; Giura, M.T.; Rossotto, G. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 10(2022) Page Start: e838 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗